biostudies-literatureMartinez-Peinado NMinisterio de Ciencia e InnovaciónDepartament de Salut, Generalitat de Catalunya'la Caixa' Foundatione0012166https://www.ebi.ac.uk/biostudies/studies/S-EPMC11326570biostudies-literatureUnknown18(8)Chagas disease, caused by the parasite Trypanosoma cruzi, affects over 6 million people, mainly in Latin America. Two different clinical phases, acute and chronic, are recognised. Currently, 2 anti-parasitic drugs are available to treat the disease (nifurtimox and benznidazole), but diagnostic methods require of a relatively complex infrastructure and trained personnel, limiting its widespread use in endemic areas, and the access of patients to treatment. New diagnostic methods, such as rapid tests (RDTs) to diagnose chronic Chagas disease, or loop-mediated isothermal amplification (LAMP), to detect acute infections, represent valuable alternatives, but the parasite's remarkable genetic diversity might make its implementation difficult. Furthermore, determining the efficacy of Chagas diseaPLoS neglected tropical diseasesA guide for the generation of repositories of clinical samples for research on Chagas disease.PMC11326570CERCA ProgramPID2019-109090RB-100/AEI/10.13039/501100011033CEX2018-000806-SLCF/BQ/DI21/11860037Aguero FCarmen Thomas MLopez MCPinazo MJGascon JScandale IAlonso-Padilla JAlarcon de Noya BGomez ANHEPACHA Network (New Tools for the Diagnosis and Evaluation of Chagas Disease)Hasslocher-Moreno AMLosada Galvan ISchijman AGRodrigues Ferreira RTorrico FGabaldon-Figueira JCCremonini Araujo-Jorge TMartinez-Peinado NNoya-Gonzalez OMariano Ruiz ARojas GGonzalez Martinez ABeron SMagalhaes Saraiva RRamsey JMaldonado RAPinto JfalseA guide for the generation of repositories of clinical samples for research on Chagas disease.Chagas disease, caused by the parasite Trypanosoma cruzi, affects over 6 million people, mainly in Latin America. Two different clinical phases, acute and chronic, are recognised. Currently, 2 anti-parasitic drugs are available to treat the disease (nifurtimox and benznidazole), but diagnostic methods require of a relatively complex infrastructure and trained personnel, limiting its widespread use in endemic areas, and the access of patients to treatment. New diagnostic methods, such as rapid tests (RDTs) to diagnose chronic Chagas disease, or loop-mediated isothermal amplification (LAMP), to detect acute infections, represent valuable alternatives, but the parasite's remarkable genetic diversity might make its implementation difficult. Furthermore, determining the efficacy of Chagas disea2024-01-01T00:00:00Z2024 Aug2025-04-21T22:06:54.203Z2025-04-05T18:37:03.717ZS-EPMC113265703914623310.1371/journal.pntd.0012166